
Monteverde and Halper Sadeh issued attorney advertisements on the proposed Element Solutions-Solstice transaction, Crinetics' sale to Vertex, and Solstice's merger with Element, seeking shareholder contacts and citing possible deal-related claims.
Monteverde & Associates PC and Halper Sadeh LLC issued July 2026 attorney advertisements seeking shareholder contacts regarding proposed transactions involving Element Solutions, Crinetics Pharmaceuticals and Solstice Advanced Materials. Both firms cited Element Solutions' proposed sale to Solstice for $10.00 in cash plus 0.500 Solstice shares per Element share, with Element shareholders expected to own about 44% of the combined company at closing; Crinetics' proposed sale to Vertex Pharmaceuticals for $85.00 per share in cash; and Solstice's merger with Element Solutions. Halper Sadeh said it is investigating potential federal securities law violations or breaches of fiduciary duties and may seek increased consideration, additional disclosures or other relief, while Monteverde said shareholders could seek more information at no cost or obligation as part of a broader set of merger and sale probes.